Ocugen, Inc. (OCGN)
Ocugen, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Ocugen, Inc. (OCGN) is a Biotechnology company based in US with a market capitalization of $470M. Revenue grew 8.8% year-over-year and free cash flow was negative at -$57.1M. This page tracks OCGN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 95 employees · IPO Dec 3, 2014
Valuation
Valuation & price
$1.39as of May 17, 2026· -44.0% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$470M
Market cap
8.8%
Revenue growth (YoY)
45.9%
Gross margin
-$57.1M
Free cash flow (USD)
$14.6M
Net debt
10.8%
Share dilution
0/4
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2022 → 2025
Value screen
Graham defensive-investor tests
1
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 8, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider buyJun 17, 2026Filing
Insider Buy $26KJohnson-Greene Treerita Essalima · Chief Financial Officer · $25.8K
- 8-K eventJun 11, 2026Filing
Annual Meeting Results
- 8-K eventJun 3, 2026Filing
Chief Accounting Officer Resignation
- 8-K eventMay 14, 2026Filing
Debt Financing
- 8-K eventMay 14, 2026Filing
Chief Medical Officer Change
- Quarterly reportMay 8, 2026Filing
10-Q Filed
- 8-K eventMay 7, 2026Filing
Convertible Notes Issued
- 8-K eventMay 5, 2026Filing
Business Update and Financial Results
- 8-K eventMay 4, 2026Filing
Convertible Notes Offering
Questions
Frequently asked questions
What is Ocugen, Inc.'s market cap?
Ocugen, Inc. (OCGN) has a market capitalization of $470M.
What is OCGN's P/E ratio?
A meaningful P/E ratio is not available for OCGN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
Are insiders buying OCGN stock?
Yes — SEC Form 4 filings show 1 open-market insider buy and 0 sells at Ocugen, Inc. in the last 90 days.
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.